Radhika Rajeev

Dr. Radhika Rajeev

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2025 in Radiology: Imaging Cancer
Verified
Journal Article
Closed access
HHHero K. Hussain
Hero K. Hussain
RRRadhika Rajeev
Radhika Rajeev
KDKristen K. DeStigter
Kristen K. DeStigter
VGVikas Gulani
Vikas Gulani
Low- and middle-income countries face disproportionate cancer morbidity and mortality and limited imaging access; targeted technologies, workforce development, infrastructure investment, and policy initiatives can help reduce these disparities.



18 September 2025 in Academic Radiology
Verified
Journal Article
Open access
RRRadhika Rajeev
Radhika Rajeev
LKLauren J. Kelsey
Lauren J. Kelsey
NSNicole Seiberlich
Nicole Seiberlich
ASAshok Srinivasan
Ashok Srinivasan
MIMohannad Ibrahim
Mohannad Ibrahim
SMShruti Mishra
Shruti Mishra
The purpose of this study is to evaluate whether the whole-body 0.55 T MRI may be a clinically acceptable or non-inferior alternative to 1.5T/3T for internal auditory canal (IAC) imaging due to greater field homogeneity and resultant reduced susceptibility artifacts near air-bone interfaces. We compare image quality, visibility of IAC anatomy, and cochlear measurements at 0.55 T vs. 1.5T/3T. In this IRB-approved retrospective study, 25 patients who underwent 0.55 T MRI using IAC protocol with prior/ subsequent comparative scans at 1.5T/3T scans were selected. A subset (n=13) also had high-resolution CT (HRCT). 3 board-certified neuroradiologists independently scored the visibility of anatomical structures and overall image quality on a 4-point Likert scale in one non-pathological ear. Readers also measured cochlear length, cochlear width, and IAC width on double oblique coronal images. All three readers rated the visualization of anatomic structures as clinically acceptable (scores ≥ 2) at 0.55 T. Two of the three readers reported no significant difference in visualization of these structures between 0.55 T and higher field strengths. Quantitative measurements (cochlear length, width, and IAC width) at 0.55 T were comparable to 1.5T/3T. One reader (R2) rated overall image quality significantly lower at 0.55 T (mean score: 3.1 at 0.55 T vs. 2.6 at HF; p = 0.005). Clinical evaluation of IAC and inner ear structures using a 3D T2w SPACE sequence at 0.55 T is an acceptable alternative to imaging at conventional field strengths of 1.5/3T.

21 May 2026 in Neurology International
Verified
Journal Article
Open access
PDF file
PRPranjal Rai
Pranjal Rai
DMDaniel Mandel
Daniel Mandel
GBGirish Bathla
Girish Bathla
VDVidhi Hiteshbhai Dhaduk
Vidhi Hiteshbhai Dhaduk
RRRadhika Rajeev
Radhika Rajeev
DLDhairya A Lakhani
Dhairya A Lakhani
Background: Asymptomatic intracranial atherosclerotic arterial stenosis (ICAS) is an underrecognized entity for which vascular risk-factor optimization is the primary management strategy, with no current indication for routine antiplatelet therapy or endovascular intervention for primary stroke prevention. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) reduce major adverse cardiovascular events, including stroke, in high-risk cardiometabolic populations, but their association with outcomes in asymptomatic ICAS is yet to be evaluated. The present study aims to evaluate the association between GLP-1RA use and cerebrovascular outcomes in adults with asymptomatic ICAS. Materials and Methods: We used the TriNetX US Collaborative Network (71 healthcare organizations) to identify adults (≥18 years) with ICAS between 1 January 2016 and 31 December 2025, and excluded patients with prior cerebral infarction, intracranial hemorrhage, or cerebrovascular ischemic syndromes. Exposure was defined as initiation of any GLP-1 receptor agonist (lixisenatide, semaglutide, liraglutide, tirzepatide, dulaglutide) during the 6 months before or on the date of index ICAS diagnosis. Outcomes were assessed at 1 year, and included ischemic stroke, all-cause mortality, and a composite of ischemic stroke or mortality. Propensity-score matching (1:1) was performed, including demographics, vascular risk factors, comorbidities, antithrombotics, lipid/diabetes therapies, and cardiometabolic laboratory/physiologic measures. Results: Before matching, 1746 GLP-1RA users and 71,792 non-users met inclusion criteria; after matching, 1728 patients remained in each cohort. GLP-1RA use was associated with lower 1-year risk of ischemic stroke (4.40% vs. 6.10%; hazard ratio [HR] 0.70, 95% CI 0.52–0.95; p = 0.044), lower all-cause mortality (3.40% vs. 9.40%; HR 0.35, 95% CI 0.26–0.47; p < 0.001), and lower composite outcome risk (7.50% vs. 15.00%; HR 0.48, 95% CI 0.39–0.59; p < 0.001). Notably, these associations were observed despite matching for HbA1c, LDL cholesterol, BMI, and systolic blood pressure, suggesting potential effects beyond measured cardiometabolic risk profiles. Conclusions: In this large, propensity-matched cohort of adults with a-ICAS, GLP-1RA use was associated with lower ischemic stroke, all-cause mortality, and composite outcome at 1 year. These findings are hypothesis-generating and require further prospective studies to confirm this observation.